Tirzepatide Recherche – Pureté 99%+

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-TZ Certificate of Analysis

GLP1-RC-TZ material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-TZ certificate evidence

Catalogue identifier: GLP1-RC-TZ

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/tirzepatide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Domaines de recherche publiés

Les études publiées examinent l’activité des récepteurs, la pharmacocinétique et des critères métaboliques, glycémiques et de insulin sensitivity définis par protocole. Les résumés ci-dessous rapportent ce que les chercheurs ont mesuré dans ces études externes et ne constituent pas des instructions d’utilisation du matériel de recherche fourni ici.

Pharmacologie des récepteurs

Puissance GIPR complète associée à une signalisation GLP-1R biaisée vers cAMP, caractérisée dans des études in-vitro publiées.

Critères métaboliques

Variation de la masse corporelle par rapport à la valeur initiale définie par protocole, mesurée dans le programme SURMOUNT.

Critères glycémiques

HbA1c comme critère défini par protocole, mesuré dans l’ensemble du programme SURPASS sur le diabète.

Critères de sensibilité à insulin

Marqueurs de insulin sensitivity et adiponectin, mesurés parallèlement à la signalisation adipeuse directe médiée par GIPR.

Pharmacocinétique

Exposition systémique, biodisponibilité et semivie apparente, d'après une caractérisation pharmacocinétique publiée.

Scientific Overview

In short: GLP1-RC-TZ est un composé de recherche double agoniste GIPR / GLP-1R, couramment appelé « Tirz » dans les communautés de recherche.

Key research facts

Pharmacologie des récepteurs : activité double agoniste GIPR / GLP-1R caractérisée dans des études in-vitro publiées

Agonisme déséquilibré rapporté — puissance GIPR complète avec une signalisation GLP-1R biaisée vers cAMP par rapport au recrutement de β-arrestin

Substitutions Aib2 et Aib13 étudiées pour la résistance à DPP-IV et aux protéases

La modification C20 fatty-diacid est rapportée comme donnant 99% de liaison à l’albumine ; la demi-vie apparente d’élimination est rapportée à ~5 jours

SURMOUNT-1 RCT (NEJM 2022, PMID 35658024), bras 15 mg : les investigateurs ont rapporté une variation moyenne du poids corporel de −20.9% par rapport à l'inclusion à la semaine 72

These points summarise lab themes, not human outcomes.

Les travaux publiés caractérisent la pharmacologie des récepteurs, les modifications structurelles et le profil pharmacocinétique de cette classe de composés, parallèlement à des critères définis par protocole étudiés dans des programmes cliniques enregistrés.

La vérification des lots New-U et la littérature externe constituent deux ensembles de preuves distincts : les analyses de lot établissent l’identité analytique et la pureté du matériau testé ; les études publiées décrivent leurs propres matériaux et protocoles expérimentaux.

Architecture moléculaire

LY3298176 est un peptide synthétique de 39 acides aminés caractérisé dans des études de pharmacologie réceptrice comme agoniste de deux récepteurs incrétines, GLP-1R et GIPR, plutôt que de GLP-1R seul.

Pharmacologie des récepteurs

La littérature décrit le profil comme déséquilibré : une puissance GIPR complète superposée à un signal GLP-1R orienté vers cAMP. Tableau complet des voies : Receptor Pharmacology ci-dessous.

Modifications structurelles

Les travaux structurels publiés décrivent des substitutions Aib2 et Aib13 étudiées pour la résistance aux protéases et un C20 fatty diacid attaché à Lys20 via un spacer γGlu/AEEA, étudié comme facteur de liaison à l’albumine contribuant à une exposition systémique prolongée.

Pharmacocinétique publiée

La demi-vie apparente d’élimination est rapportée à environ cinq jours, avec environ 80% de biodisponibilité sous-cutanée. Profil complet : Pharmacokinetics ci-dessous.

Recherche clinique

Les résultats publiés résumés sur cette page concernent des études cliniques externes du médicament de référence et leurs matériels et protocoles respectifs. Ils n’établissent pas la sécurité, l’efficacité ou l’équivalence clinique du matériel New-U GLP1-RC-TZ.

Références principales

Les publications évaluées par les pairs et les dossiers d’essais enregistrés sont listés intégralement, avec les identifiants DOI/PMID/NCT, dans Source References ci-dessous.

At a glance

Mechanism and receptors Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Clinical research SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme.

Molecular characteristics Molecular weight 4,813.53 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Receptor Pharmacology

Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GIPR Full agonist activity characterised experimentally, comparable to native GIP The arm that distinguishes the dual agonist from single GLP-1R compounds in the literature GLP-1R Agonist activity characterised as biased, favouring cAMP signalling over β-arrestin recruitment Investigated in relation to receptor desensitisation over prolonged exposure Adipose GIPR signalling Direct GIPR-mediated adipose effects characterised experimentally Investigated as a contributor to measured insulin-sensitivity markers and adiponectin Albumin-binding modification C20 eicosanedioic acid via a γGlu/AEEA spacer; 99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~5-day apparent half-life) Proteolytic stability Aib2 and Aib13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and proteases

Deeper dive for scientific readers

The imbalanced-agonism profile is characterised in JCI Insight (2020): full GIPR potency layered onto a cAMP-biased GLP-1R signal. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024) investigators reported a mean change from baseline in body weight of −20.9% at week 72 in the 15 mg arm. SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) was designed as a head-to-head comparison against semaglutide and reported −20.2% vs −13.7% at week 72. SURPASS-CVOT (NEJM 2025) compared cardiovascular outcomes against dulaglutide and reported an approximately 8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality. Insulin-sensitivity improvements beyond what change in body weight alone accounts for are discussed in the literature as consistent with direct GIPR-mediated adipose effects. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

Qu'est-ce que Tirzepatide dans la recherche scientifique ?

Tirzepatide (LY3298176) est un peptide synthétique de 39 acides aminés caractérisé dans des études de pharmacologie des récepteurs comme agoniste double des récepteurs GIP / GLP-1 avec un agonisme déséquilibré. Il est approuvé comme médicament dans certaines juridictions sous des noms de marque d'autres fabricants; le matériel fourni ici n'est pas ce produit pharmaceutique fini.

Qu'est-ce que GLP1-RC-TZ ?

GLP1-RC-TZ est l’identifiant de catalogue New-U pour le matériel de recherche en laboratoire proposé dans ce profil de recherche. Ce n’est pas un médicament, un traitement, un générique pharmaceutique ou un produit thérapeutique ; il n’est équivalent à aucun produit clinique ou commercial et n’est pas proposé pour un usage humain ou vétérinaire.

Quels systèmes de récepteurs sont examinés dans la recherche sur Tirzepatide ?

La pharmacologie in-vitro publiée caractérise deux récepteurs : GIPR, où la puissance agoniste est rapportée comme comparable à GIP natif, et GLP-1R, où la signalisation est rapportée comme biaisée vers la génération de cAMP par rapport au recrutement de β-arrestin. Les travaux structurels étudient également la modification C20 fatty-diacid de liaison à l’albumine et les substitutions Aib2/Aib13 pour une stabilité protéolytique modifiée.

Quels tests analytiques accompagnent GLP1-RC-TZ ?

The published GLP1-RC-TZ Certificate of Analysis comes from an independent analytical laboratory and records the independent laboratory, report number, measured purity and test date for the sample analysed; the method and any identity result are stated on the report itself. Vials are not batch-marked, so a certificate describes the sample tested rather than a particular vial or order. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current Certificate of Analysis for GLP1-RC-TZ?

The current certificate — laboratory, report number, measured purity and test date — is published at /coa/tirzepatide, together with the testing history for the compound.

Que signifie une pureté HPLC >99% ?

Il s’agit d’une valeur de pureté obtenue par reversed-phase high-performance liquid chromatography avec normalisation de l’aire : le pic cible représente plus de 99% de l’aire intégrée totale des pics du chromatogramme pour l’échantillon testé. Cette valeur décrit uniquement la pureté chimique de cet échantillon et ne dit rien de la stérilité, de la teneur en endotoxines, de l’équivalence pharmaceutique ou de toute propriété clinique.

Quels essais cliniques sont référencés sur cette page ?

Trois études externes sur le médicament de référence : SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) et SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), ainsi que la caractérisation pharmacologique des récepteurs dans JCI Insight (2020). Chaque résultat rapporté sur cette page est attribué à son étude, son bras et son point temporel.

Comment la recherche clinique publiée est-elle distinguée des analyses de lots New-U ?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U certificate testing is analytical work on a submitted sample of the GLP1-RC-TZ material: the published report states the measured result for the sample analysed, and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-TZ.

GLP1-RC-TZ est-il identique à un médicament de marque approuvé ?

Non. Les produits de marque tirzepatide approuvés sont des produits pharmaceutiques finis, stériles et sur prescription, fabriqués selon cGMP par leur titulaire d’autorisation de mise sur le marché. GLP1-RC-TZ est du matériel de recherche en laboratoire non approuvé fourni sous forme de poudre lyophilisée. Il n’est ni équivalent, ni générique, ni substitut de tout produit approuvé.

Pourquoi Tirzepatide est-il décrit comme déséquilibré dans la littérature ?

Parce que les deux bras récepteurs ne sont pas équilibrés : la pharmacologie publiée rapporte une puissance agoniste complète sur GIPR comparable à GIP natif, mais une signalisation biaisée sur GLP-1R qui favorise la génération de cAMP plutôt que le recrutement de β-arrestin. La littérature étudie cette asymétrie en lien avec la désensibilisation des récepteurs lors d’une exposition prolongée.

En quoi la recherche sur Tirzepatide diffère-t-elle de celle sur Retatrutide et Semaglutide ?

Selon la couverture des récepteurs caractérisée dans la littérature : la recherche sur semaglutide décrit un agonisme GLP-1R, celle sur tirzepatide un agonisme GIPR/GLP-1R, et celle sur retatrutide étudie un agonisme GLP-1R/GIPR/GCGR. Seul SURMOUNT-5 a été conçu comme comparaison directe (tirzepatide vs semaglutide) ; les résultats issus de programmes distincts ne sont pas des comparaisons directes.

Sous quelle forme GLP1-RC-TZ est-il fourni ?

GLP1-RC-TZ is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths; the Certificate of Analysis is published on the product page.

Comment le matériel de recherche en laboratoire doit-il être conservé ?

Conserver la poudre lyophilisée dans un congélateur à −20 °C. Si un protocole de laboratoire exige le matériel en solution, maintenir la solution obtenue au réfrigérateur à 1–6 °C, à l'abri de la lumière, et éviter les cycles répétés de congélation-décongélation, qui peuvent dégrader la modification fatty-acid. Les conditions de stockage constituent uniquement des informations de manipulation en laboratoire.

Is it legal to buy Tirzepatide?

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 8–72 h Bioavailability ~80% subcutaneous reported Metabolism / clearance Proteolytic backbone cleavage, β-oxidation of the C20 fatty-diacid chain and amide hydrolysis reported; metabolites eliminated ~66% renally / ~33% faecally; no CYP-mediated interactions Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~10.3 L; 99% albumin-bound. These are pharmacokinetic observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

SURMOUNT-1 RCT (Jastreboff et al., NEJM 2022; PMID 35658024), obesity/overweight population, 15 mg arm: investigators reported a mean change from baseline in body weight of −20.9% at week 72

SURMOUNT-5 head-to-head RCT (Aronne et al., NEJM 2025; PMID 40353578): investigators reported −20.2% in the tirzepatide arm vs −13.7% in the semaglutide arm at week 72

SURPASS-CVOT RCT (NEJM 2025), 13,000+ participants vs dulaglutide: investigators reported an ~8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality

SURPASS diabetes programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Insulin-sensitivity markers and adiponectin recorded as measured endpoints, discussed in the literature in relation to direct GIPR-mediated adipose signalling

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The SURPASS and SURMOUNT programmes included 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg arms, with a protocol-defined step-up period of roughly 20 weeks before the maintenance arm level was reached. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite and dyspepsia recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Hypersensitivity and injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Tier 1 · Human clinical

SURMOUNT-1 obesity RCT — −20.9% mean change from baseline in body weight at week 72 (NEJM 2022; PMID 35658024)

SURMOUNT-5 head-to-head RCT vs semaglutide — −20.2% vs −13.7% at week 72 (NEJM 2025; PMID 40353578)

SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. · 2022 · PMID: 35658024 · DOI: 10.1056/NEJMoa2206038

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2505928

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

39-amino-acid synthetic peptide built on the GIP backbone (LY3298176)

Dual GIPR / GLP-1R agonist activity characterised with imbalanced agonism

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding

Apparent elimination half-life reported at approximately 5 days in published pharmacokinetic research

GLP1-RC-TZ laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

Identifiant de catalogue New-U GLP1-RC-TZ Sujet scientifique Tirzepatide (LY3298176) Masse moléculaire 4,813.53 Da Récepteurs caractérisés GIPR (agoniste complet), GLP-1R (biaisé cAMP) Pureté (analytique) >99% par normalisation de l’aire RP-HPLC Identité (analytique) Stated on the published Certificate of Analysis where the report includes an identity test Forme Poudre lyophilisée Demi-vie publiée Environ 5 jours, moyenne de 116.7 h (recherche pharmacocinétique externe) Conservation Lyophilisé : congélateur à −20 °C. Reconstitué : 1-6 °C, à l'abri de la lumière. Utilisation prévue Laboratory research material. Not for human or veterinary use.

Tirzepatide Research — GLP1-RC-TZ Laboratory Research Material

Tirzepatide is the most extensively characterised dual-incretin ("twincretin") peptide in the published literature. Receptor-pharmacology studies describe full GIPR agonist potency layered onto a cAMP-biased GLP-1R signal, and the clinical programme includes one trial, SURMOUNT-5 (NEJM 2025), specifically designed as a head-to-head comparison against semaglutide.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −20.9% at week 72 in the SURMOUNT-1 15 mg arm (NEJM 2022), −20.2% vs −13.7% against semaglutide at week 72 in SURMOUNT-5 (NEJM 2025), an ~8% relative reduction in major adverse cardiovascular events against dulaglutide in SURPASS-CVOT (NEJM 2025), and HbA1c reductions of up to 2.58% in the SURPASS programme. Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-TZ as lyophilised, analytically verified laboratory research material ; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material. GLP1-RC-TZ is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Customer Reviews

Everything arrived safely

Order reached me in good condition and the contents matched the basket. All good here.

- Channan R***** · 20 October 2026

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Tirzepatide vs related Metabolic Research compounds

Compound Price Purity spec COA Tirzepatide from $168 >99% HPLC 2 published batches Retatrutide from $160 >99% HPLC 4 published batches Semaglutide from $106 >99% HPLC 1 published batch

Tirzepatide vs Retatrutide - full comparison

Tirzepatide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tirzepatide

Metabolic Research research compounds

Tirzepatide research guide

Tirzepatide pricing and packs

Research this compound

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Compare Compare Tirzepatide and Liraglutide Tirzepatide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Tirzepatide COA Latest published certificate of analysis (purity and identity), dated 2026-05-27. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research